Related Experiment Video
Updated: Mar 27, 2026

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells
Published on: March 7, 2025
Risk of endocrine complications in cancer patients treated with immune check point inhibitors: a meta-analysis
Omar Abdel-Rahman1, Hesham ElHalawani1, Mona Fouad2
1Clinical Oncology Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt.
Background:
We performed a meta-analysis of the risk of endocrine adverse events associated with immune check point inhibitors.
Methods:
Eligible studies included randomized trials of cancer patients on immune checkpoint inhibitors; describing events of hypothyroidism, hyperthyroidism, hypophysitis and adrenal insufficiency.
Results:
A total of ten clinical trials were eligible for the meta-analysis. The relative risk of all-grade hypothyroidism, hyperthyroidism, hypophyisitis and adrenal insufficiency were 8.26 (95% CI: 4.67-14.62; p < 0.00001), 5.48 (95% CI: 1.33-22.53; p = 0.02); 22.03 (95% CI: 8.52-56.94; p < 0.00001), 3.87 (95% CI: 1.12-13.41; p = 0.03), respectively.
Conclusion:
Our meta-analysis has demonstrated that the use of immune check point inhibitors is associated with an increased risk of hypothyroidism, hyperthyroidism, hypophysitis and adrenal insufficiency compared with control.
Related Concept Videos
Psychoneuroimmunology: Diabetes and Cancer
Tumor Immunotherapy
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Cancer Therapies
The Tumor Microenvironment
Disorders of the Female Reproductive System
